N atriuretic peptides (NPs) are diuretic and vasodilatory hormones synthesized from the heart in response to increased myocardial wall stress. 1 A previous study reported that an NP deficiency state exists in obesity 2 and in individuals with common genetic variants. 3 Whether there are differences in NP levels by race is not well understood. Prior studies reported no differences in NP levels by race. 4, 5 However, 2 recent population studies suggested that black individuals have lower N-terminal pro-B-type NP (NTproBNP) levels as compared with white individuals. 6, 7 These data are potentially important in that an endogenously suppressed NTproBNP system could contribute to a higher risk of hypertension and heart failure in black individuals as compared with white individuals. The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study 8 offers a unique opportunity to characterize plasma NTproBNP levels according to race in a large study of participants free of cardiovascular and kidney disease. We sought to examine the hypothesis in these healthy individuals that plasma NTproBNP levels would be lower in black individuals as compared with white individuals. In addition, we tested whether racial differences in NP levels are associated with dissimilar rates of all-cause mortality, CV mortality, non-CV mortality, and incident hypertension in black and white participants in the REGARDS study.
Methods

Assembly of Cohort
The REGARDS study is a national population-based cohort study evaluating racial and geographic disparities in stroke in US adults 45 years of age or older. 8 Participants were excluded from the REGARDS study if they self-identified as Hispanic white individuals or Hispanic black individuals. Details of the study design were described previously. 8 The demographic, socioeconomic, and medical information along with verbal informed consent was obtained by computer-assisted telephone interview, which was followed by an in-home visit at which written informed consent, blood pressure (BP), anthropomorphic measures, blood samples, electrocardiogram results, and medication inventory were obtained. 8 The University of Alabama at Birmingham, University of Vermont, Wake Forest University School of Medicine, University of Arkansas for Medical Sciences, University of Cincinnati, and Indiana University Institutional Review Boards approved the study protocol.
A stratified random cohort of 4415 participants was selected for NTproBNP measurement. Stratification factors included age, sex, and race. These participants underwent NTproBNP measurements using stored samples from baseline. Fasting baseline blood samples were drawn and stored using standardized methods.
9 N-terminal pro-B-type NP was measured in the random cohort sample using an electrochemiluminescence immunoassay (Roche Elecsys 2010; Roche Diagnostics; coefficient of variation, <5%). To address our hypothesis of NP suppression by race, we excluded 2417 participants for the following reasons: missing NTproBNP levels (n = 283), prevalent CV disease (n = 1327; defined as individuals with coronary artery disease [including coronary artery bypass grafting, percutaneous coronary interventions, self-reported myocardial infarction, or presence of myocardial infarction on electrocardiogram results as defined by the Minnesota code 10 ], stroke, transient ischemic attack, atrial fibrillation, peripheral vascular disease, and aortic aneurysm), heart failure (n = 608), or estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 (n = 199). 11 We conducted our analysis among the remaining 1998 participants from July 1, 2003, to September 12, 2007.
Measurements and Definitions
Hypertension was defined as systolic BP of 140 mm Hg or more and diastolic BP of 90 mm Hg or more or self-reported hypertension with use of antihypertensive medications. Diabetes was defined by self-report with use of oral antidiabetic medications or insulin, fasting glucose more than 126 mg/dL (to convert to millimoles per liter, multiply by 0.0555), or nonfasting glucose more than 200 mg/dL. Hyperlipidemia was defined by total cholesterol of 240 mg/dL or more (to convert to millimoles per liter, multiply by 0.0259), low-density lipoprotein cholesterol of 160 mg/dL or more (to convert to millimoles per liter, multiply by 0.0259), high-density lipoprotein cholesterol of 40 mg/dL or less (to convert to millimoles per liter, multiply by 0.0259), or self-reported use of antihyperlipidemic medications. Aspirin use was selfreported. Atrial fibrillation was defined by self-report or from presence on electrocardiogram. Baseline stroke and transient ischemic attack were defined by self-report. Heart failure was defined as presence of orthopnea or paroxysmal nocturnal dyspnea or NTproBNP levels greater than 300 pg/mL. 12 Smoking, alcohol use, exercise, educational level, and income status were self-reported. Peripheral vascular disease and history of aortic aneurysm repair were self-reported. Renal dysfunction was defined as estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 .
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All-Cause Mortality, Cause-Specific Mortality, and BP Measures
After the baseline examination for the REGARDS study, routine semiannual interviews were conducted. If it was not possible to reach participants, mortality was assessed through contact with proxies. The date of death was corroborated through death certificates or the national death index, as described previously. 13 Our analyses in this article are based on deaths that occurred through March 2016.
Key Points
Question Does primary natriuretic peptide deficiency exist in black individuals?
Findings In this cohort study, N-terminal pro-B-type natriuretic peptide levels were 27% lower in black individuals as compared with white individuals, tested in a stratified random subgroup from a national cohort; these findings were consistent when meta-analyzed with other population-based cohorts. There was a robust association of natriuretic peptide levels with all-cause mortality driven by cardiovascular mortality in individuals free of prevalent cardiovascular and renal disease that did not differ by race.
Meaning Black race is a natriuretic peptide deficiency state; the prognostic value of natriuretic peptide levels in a population-based cohort is similar in black and white individuals.
In the REGARDS study, cause of death was adjudicated by a committee of physicians using information from death certificates, hospital records, and interviews with proxies. These centrally adjudicated CV and non-CV mortality characterizations were used for our analyses. 13 Briefly, CV mortality was defined as death from any of the following adjudicated events: myocardial infarction, stroke, sudden death, heart failure, pulmonary embolism, noncardiac CV disease, and other cardiac causes of death. Any other deaths apart were considered as non-CV deaths. Incident hypertension was determined in participants free from the diagnosis of hypertension at the baseline visit. Longitudinal BP progression was assessed as change in systolic and diastolic BP at the second visit from the baseline visit. Description of incident hypertension ascertainment and longitudinal changes in BP along with details of the second visit are described in the eAppendix in the Supplement.
Statistical Analysis
Statistical analysis was conducted from July 1, 2003, to March 31, 2016, using STATA, version 14.0 MP (StataCorp LP). Differences in baseline characteristics among black and white individuals were compared using χ 2 tests for categorical variables and the MannWhitney test for continuous variables. Cumulative distribution curves of NTproBNP levels by race were constructed to assess racial differences. Associations of NTproBNP with race were evaluated by linear regression models, including unadjusted, age-and sex-adjusted, and multivariable models. Natural log-transformed NTproBNP was the dependent variable for all models. Covariates in multivariable models were included if they were known to clinically affect NTproBNP levels or were included in previous studies. 6, 7 These variables included age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), systolic BP, antihypertensive medications, aspirin use, hyperlipidemia, income, smoking, exercise, and estimated glomerular filtration rate. White race was chosen as a reference, and the percentage difference with 95% CI was calculated using the formula: (e β − 1) × 100 (where β is the beta coefficient from linear regression). Appropriate modeling techniques were used to estimate the association of natural log-transformed NTproBNP levels and race with outcomes described above. The details of these analyses are described in the eAppendix in the Supplement.
Meta-analysis With Other Cohort Studies
Our literature search revealed 2 studies assessing racial differences in NTproBNP using the identical NTproBNP assay, the Dallas Heart Study (DHS) 6 and Atherosclerosis Risk in Communities (ARIC) study. 7 The β estimates for log-transformed NTproBNP levels in multivariable models (adjusted for similar factors across 3 cohorts) were meta-analyzed using random effects modeling. The details of these analyses are described in the eAppendix in the Supplement.
Results
Our assembled cohort included 1998 participants with me- 
NTproBNP and Race
The median NTproBNP level in black participants was significantly lower than in white participants (46 pg/mL [IQR, 23-91] vs 60 pg/mL [IQR, 33-106]; P < .001) ( Table 1 ). The cumulative distribution plots of NTproBNP levels by race showed that NTproBNP levels were lower in black participants as compared with white participants (eFigure 1 in the Supplement). The adjusted absolute differences in log NTproBNP levels by race are shown in Table 2 . In the unadjusted model, NTproBNP levels were 21% lower in black participants. After adjusting for age and sex, the NTproBNP levels were 23% lower in black participants, and were 27% lower in the fully adjusted model (Table 2) .
To assess the use of thiazide or loop diuretics as a possible residual confounder contributing to the observed racial differences in NTproBNP levels, we conducted the above analyses in 1515 participants not taking any diuretic medications and found comparable racial differences in NTproBNP levels as in the study cohort of 1998 individuals (eTables 1 and 2 in the Supplement).
Meta-analysis of Other Cohort Studies
We included the REGARDS study, the DHS, and the ARIC study for this analysis. The number of participants without prevalent CV disease in the REGARDS study was 1998, in the DHS was 2575, and in the ARIC study was 9137. There were 981 black participants (49.1%) in the REGARDS study, 1606 of 2575 (62.4%) in the DHS, and 1973 of 9137 (21.6%) in the ARIC study. The median NTproBNP levels in black participants were 46 pg/mL (IQR, 23-91 pg/mL) in the REGARDS study, 24 pg/mL (IQR, 10-52 pg/mL) in the DHS, and 43 pg/mL (IQR, 18-88 pg/mL) in the ARIC study. The participants in the REGARDS study were oldest, with a median age of 63 years (IQR, 54-72 years), followed by the ARIC study, in which the median age was 61 years (IQR, 57-67 years), and the DHS, in which the median age was 44 years (IQR, 36-52 years). In all 3 cohorts, NTproBNP levels in black participants were significantly lower than in white participants. The highest multivariableadjusted percentage difference by race was observed in the ARIC study (40% lower in black participants), whereas the lowest multivariable-adjusted percentage difference was observed in the REGARDS study (27% lower in black participants) as compared with white participants (Figure 1 ). Pooling cohorts, multivariable-adjusted NTproBNP was 35% lower in black vs white participants (I 2 =86%;P < .001) (Figure 1 ).
Mortality, Incident Hypertension, and Longitudinal Changes in BP in REGARDS Study Participants
In the 1998 REGARDS study participants, a total of 279 individuals (155 black participants and 124 white participants) died during a median follow-up period of 8.4 years (IQR, 6.9-10.7 years). In unadjusted models, for every 1-SD increment in log NTproBNP levels, there was an 87% increase in the risk of death for the overall population (hazard ratio [HR], 1.87; 95% CI, 1.64-2.13; P < .001). Results were similar in the age-, sex-, and raceadjusted model (HR, 1.43; 95% CI, 1.24-1.66; P < .001) and the multivariable model (HR, 1.31; 95% CI, 1.11-1.54; P = .001) ( Table 3) . This increase was driven by the association of NTproBNP with CV mortality (multivariable model: HR, 1.69; 95% CI, 1.19-2.41; P = .004) ( Table 3 ). We did not observe an association between NTproBNP levels and non-CV mortality (multivariable model: HR, 1.20; 95% CI, 1.00-1.46; P = .06)(Table3). A total of 978 participants were normotensive at baseline. Of these 978, 529 participants had their hypertension status ascertained at the second in-home visit. Among those participants, 187 (35.3%) developed hypertension. We did not observe any association between NTproBNP levels and incident hypertension or progression of systolic or diastolic BP (eTables 3, 4, and 5 in the Supplement).
Effect of Race on Association Between NTproBNP and Mortality, Incident Hypertension, and BP Progression
The association of NTproBNP with incidence of all-cause mortality, CV mortality, and non-CV mortality using restricted cubic splines, stratified by race, are shown in Figure 2 . After multivari- Abbreviations: eGFR, estimated glomerular filtration rate; NTproBNP, N-terminal pro-B-type natriuretic peptide.
a Multivariable linear regression models using natural log-transformed NTproBNP as the dependent variable and race as the independent variable were used. Values shown are β coefficient (95% CI), which are on the log NTproBNP scale. Percentage lower than white participants is the estimated percentage difference in NTproBNP levels in black vs white participants, which was calculated by using the formula (e β − 1) × 100, assuming all other variables in the model remained constant.
able adjustment for established risk factors, there were no significant differences in incident rates of all-cause mortality (likelihood ratio [LR] χ 2 = 0.30; P = .96), CV mortality (LR χ 2 = 3.23; P = .36), and non-CV mortality (LR χ 2 = 1.78; P = .62) in black participants as compared with white participants. In addition, there was no interaction between race and NTproBNP levels on allcause mortality (LR χ 2 = 0.23; P = .89), CV mortality (LR χ 2 = 2.76; P = .25), and non-CV mortality (LR χ 2 = 1.78; P = .41).
We also did not observe any difference in the risk of incident hypertension in black vs white participants in the multivariableadjusted model (odds ratio, 0.93; 95% CI, 0.70-1.23; P = .61) or an interaction between race and NTproBNP on the risk of incident hypertension in the multivariable logistic regression model (odds ratio, 1.10; 95% CI, 0.69-1.77; P = .68). The association of NTproBNP levels with longitudinal change in systolic and diastolic BP stratified by race are shown in eFigures 2 and 3 in the Supplement. There was no association or racial interaction between NTproBNP and change in systolic or diastolic BP.
Discussion
In our well-characterized random cohort of participants from the REGARDS study, black participants had significantly lower plasma NTproBNP levels than white participants. This difference was significant after adjusting for multiple clinically relevant factors and remained consistent when meta-analyzed with other large population-based cohorts. Furthermore, we observed that baseline NTproBNP levels were associated with the risk of future all-cause and CV mortality. These associations were not modified by race. Last, we did not observe any association between NTproBNP levels and incident hypertension or BP progression in our subgroup analyses. However, these analyses were conducted in a subgroup of our population and were not adequately powered to detect small differences in incident hypertension and BP progression.
N-terminal pro-B-type NP is produced in response to stretch on cardiomyocytes owing to effects of hemodynamic challenges on the heart and the NP system. 14, 15 We noted that percentage differences in NTproBNP levels in black participants became more pronounced ( Two recent studies by Gupta et al 6, 7 reported racial differences in NTproBNP levels in the DHS 6 and ARIC study cohorts.
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The direction of results from our study is in concordance with the findings from these 2 studies. We observed an adjusted difference of 27% lower NTproBNP levels in black participants as compared with white participants, whereas in DHS and the ARIC study this difference was up to 40%. However, there are several differences worth mentioning. Although participants in our study were older, we had equal representation of black and white participants. Moreover, we used additional stringent criteria compared with previous studies to exclude participants with prevalent CV disease. We excluded participants with peripheral vascular disease, aortic aneurysm repair, estimated glomerular filtration rate less than 60 mL/min/ 1.73 m 2 , which the earlier studies 6,7 did not. To our knowledge, ours is the first study to summarize the percentage difference in black vs white individuals in participants free of prevalent CV disease across 3 different cohorts, which lends more generalizability to our results. Our findings suggest that NTproBNP levels are lower in black vs white individuals, which makes the argument for reporting race-specific NTproBNP values in individuals free of prevalent CV and renal disease. This finding is particularly relevant since American College of Cardiology and American Heart Association guidelines 23 provide cutoff values of NTproBNP levels that are not stratified by race to rule out heart failure in ambulatory patients. The association of elevated NP levels with adverse outcomes in apparently healthy white individuals was established by the work done by Wang and colleagues. 24 These findings were replicated in multiple studies in the general population, [25] [26] [27] although most of the studies included predominantly white participants. This association of increasing NP levels with increasing mortality has been thought to be owing to the presence of subclinical CV disease, which exists even in apparently healthy individuals. The association of NTproBNP levels with higher risk of CV risk and mortality has been described among black individuals with hypertensive kidney disease. 28 To our knowledge, there are no studies testing the association of NTproBNP levels and mortality by race in apparently healthy individuals. To our knowledge, our study is the first to report an increasing risk of all-cause mortality and CV mortality with increasing NTproBNP levels, and that this association was not modified by race in individuals free of prevalent CV and kidney disease. This finding suggests that higher NTproBNP levels are associated with similar increases in the risk of all-cause mortality in black and white individuals even though black individuals on average have lower NTproBNP levels than white individuals. This finding highlights the importance of the fact that studying the effects of NP deficiency (eg, black race) using population cohorts as a model system can be challenging owing to the involvement of the NP axis in a feedback loop. Lower levels of NTproBNP may contribute to an excess burden of CV outcomes such as heart failure and other CV events seen in black individuals. This notion is supported by genetic association studies where common genetic variants associated with an approximately 20% decrease in NP levels are associated with an approximately 15% increase in the risk of systolic BP, diastolic BP, and hypertension. 29 To summarize, we believe that NP deficiency (in black individuals) may be associated with development of CV disease, whereas association of elevated NP levels with mortality reflects the consequence of subclinical CV disease in apparently healthy individuals. This association highlights our inability to provide mechanistic insights using an epidemiologic cohort as a model system. Overall, our findings are of public health and clinical importance as NP deficiency seen in black individuals may be contributing to racial disparities in the burden of CV disease. Additional studies are required to establish and confirm the role of the NP system in the development of CV disease.
Strengths and Limitations
Our study was a well-characterized cohort of black and white individuals with a standardized collection of data at baseline and careful documentation of mortality. Despite this, study limitations require consideration. Race was selfidentified, instead of using genetic ancestry information markers, which may have resulted in misclassification. We did not have direct noninvasive assessment of left ventricular size and/or function. However, to overcome this limitation, we excluded all participants with orthopnea, paroxysmal nocturnal dyspnea, or NTproBNP levels greater than 300 pg/mL. Small sample size and lack of time to event date for incident hypertension limits our ability to determine any effects that hypertension had on mortality. We adjusted for all the known factors that can affect NP levels but there still remains the issue of unidentified confounders. Last, our conclusion that the endogenous NP system is suppressed in black individuals as compared with white individuals is based primarily on studying differences in plasma NTproBNP levels. Other NPs including mature B-type NP, N-terminal-pro-atrial type NP, and mature atrial NP were not measured in the REGARDS study.
Conclusions
We have established lower NTproBNP levels in black vs white adults in our population cohort that was free of prevalent CV and renal disease. Similar associations were observed in other cohorts. Endogenous suppression of the NP system in black individuals did not affect the association between NTproBNP levels and all-cause or cause-specific mortality, which needs to be confirmed in other cohorts. The details of second visit have been described previously. 2 Briefly, the second in-person visit for REGARDS started in 2013 after the institutional review boards of all participating universities approved the study. Participants were assessed using a similar protocol approximately 10 years after the baseline visit. Through 2015, ~87% participants had completed telephone-administered risk factor assessments with ~12% participants declining participation in the second assessment. Among those participants who agreed to participate ~72% in-person assessments have been performed. All participants provided signed informed consent at baseline and follow-up visits. Given the presence of 1) prevalent hypertension in 51% of participants in our cohort, 2) ongoing second visits, and 3) lack of time to incident hypertension data collection, our sample size/power for incident hypertension and BP progression analyses was reduced significantly.
Statistical Analysis
Analysis was performed using STATA 14.0 MP (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). Differences in baseline characteristics among blacks and whites were compared by 2 tests for categorical and Mann-Whitney U test for continuous variables. Cumulative distribution curves of Nterminal-pro B type natriuretic peptide (NTproBNP) levels by race were constructed to assess racial differences. Associations of NTproBNP with race were evaluated by linear regression models including; 1) unadjusted; 2) age and sex adjusted; 3) multivariable models. Natural log-transformed NTproBNP was the dependent variable for all models. Covariates in multivariable models were included if they were known to clinically affect NTproBNP levels or were included in previous studies. 3, 4 These variables included age, sex, body mass index, systolic BP, antihypertensive medications, aspirin use, hyperlipidemia, income, smoking, exercise, and eGFR. White race was chosen as a reference, and the percentage difference with 95% confidence interval was calculated using the formula: (e -1) x 100 ( is the beta coefficient from linear regression). We also conducted sensitivity analysis to assess the residual confounding of thiazide/loop diuretic use. Those participants on loop and thiazide diuretic were excluded and all above analyses were conducted in n=1,515 participants not on any diuretic medications.
Cox Proportional Hazard modeling was used to estimate the association of natural log-transformed NTproBNP levels with all-cause mortality, and cause-specific mortality in unadjusted and adjusted models. Covariates in multivariable models were included if they were known to clinically affect NTproBNP levels or were included in previous studies. 3, 4 The proportional-hazards assumption was tested based on Schoenfeld residuals. To plot the relationship of NTproBNP and outcomes, we used multivariable adjusted restricted cubic splines models. The variables used in models are mentioned above. Poisson modelling with three knots at 10 th , 50 th and 90 th centile of NTproBNP (modeled as a linear continuous variable) was used to plot relationship between NTproBNP levels and all-cause mortality, cardiovascular (CV) mortality, and non-CV mortality.
Logistic regression was used to assess the association between Natural log-transformed NTproBNP levels and incident hypertension in unadjusted and adjusted models. Covariates in multivariable models were included if they were known to clinically affect NTproBNP levels or were included in previous studies. 3, 4 We also compared the risk of incident hypertension in blacks versus whites in the multivariable models. We also assessed the interaction between race and Natural log-transformed NTproBNP levels on risk of incident hypertension using in the multivariable model.
Linear regression was used to estimate the association between longitudinal changes in both systolic and diastolic BP and natural log-transformed NTproBNP levels in adjusted and unadjusted models. Covariates in multivariable models were included if they were known to clinically affect NTproBNP levels or were included in previous studies. 3, 4 We also assessed interaction of NTproBNP levels and race on mortality outcomes in the aforementioned models. Linear regression model with restricted cubic splines and three knots at 10 th , 50 th , and 90 th centile of NTproBNP (modeled as a linear continuous variable) were used to plot relationship between change in systolic and diastolic BP, and assess interaction between race and NTproBNP on BP changes.
Meta-Analysis with Other Cohort Studies
Our systematic literature search revealed two studies assessing racial differences in NTproBNP, the Dallas Heart Study (DHS) and Atherosclerosis Risk in Communities (ARIC) using identical NTproBNP assay. 3, 4 We utilized standard meta-analytic techniques to estimate and pool the percentage difference in NTproBNP in blacks compared to whites. The -estimates for log transformed NTproBNP in multivariable models (adjusted for similar factors across three cohorts) were pooled meta-analyzed using random effects model. 5, 6 Random effects models were used due to the observational nature of the data, with the underlying assumption that data comes from varied populations with different distributions. The study and pooled estimates were transformed into percent differences between blacks and whites using the aforementioned formula and presented in a forest plot. Values shown were odds ratio (95% confidence interval) for every one standard deviation increment of natural log of baseline plasma NTproBNP levels in logistic regression models. Incident hypertension analyses were conducted in 529 out of 1,998 participants (who were free of hypertension at the baseline visit and had hypertension status ascertained at second visit). *: There was no interaction between race and natural log plasma NTproBNP levels on risk of incident hypertension (OR, 1.10; 95% CI, 0.69-1.77; P=0.68). 
